RSS

lenvatinib mesylate

The European Commission (EC) has granted a marketing authorisation for the oral receptor tyrosine kinase (RTK) inhibitor, LENVIMA (lenvatinib mesylate), as first-line treatment for adults with advanced or unresectable hepatocellular carcinoma (HCC). Read more

News